The methods to consider when analyzing the outcomes of myeloma clinical trials have been expanded in the European Group for Blood and Bone Marrow Transplant/ International Bone Marrow Transplant Registry. This revised form of International Response Criteria may possibly be widely used in future clinical trials. Some of these improvements and expansions are the following:

• added categories for stringent complete response and very good partial response
• added serum free light-chain assay to evaluate patients
• clarified inconsistencies from prior methods of response
• highlighted importance on time to event and response duration as critical end points.

Authors:

BGM Durie, J-L Harousseau, JS Miguel, J Blade, B Barlogie, K Anderson, M Gertz, M Dimopoulos, J Westin, P Sonneveld, H Ludwig, G Gahrton, M Beksac, J Crowley, A Belch, M Boccadaro, I Turesson, D Joshua, D Vesole, R Kyle, R Alexanian, G Tricot, M Attal, G Merlini, R Powles, P Richardson, K Shimizu, P Tosi, G Morgan and SV Rajkumar on behalf of the International Myeloma Working Group

Learn more at: